Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions

Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability. Imatinib-resistant advanced GIST continues to pose a therapeutic challenge, likely due to the frequent presence of mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Sebastian, Joensuu, Heikki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532715/
https://www.ncbi.nlm.nih.gov/pubmed/26187774
http://dx.doi.org/10.1007/s40265-015-0440-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532715/
https://www.ncbi.nlm.nih.gov/pubmed/26187774
http://dx.doi.org/10.1007/s40265-015-0440-8

Ejemplares similares